Combined antithrombotic regimens confer a higher risk of upper gastrointestinal bleeding
This article has no abstract so we have provided the first paragraph of the full text.
With the advent of antiplatelet drugs such as clopidogrel and dipyridamole, and trial results indicating the superiority of combined drug regimens for preventing thrombosis, antithrombotic treatment regimens are becoming increasingly aggressive. To assess the risk of serious upper gastrointestinal bleeding associated with more-aggressive antiplatelet therapies, and to examine the trends in prophylactic antiplatelet treatment, Hallas et al. carried out a population-based study in Funen County, Denmark.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Thrombi?beware of red cells bearing giftsNature Biotechnology News and Views (01 Aug 2003)
